biostudies-literatureUnknown57Roncali L<h4>Background and purpose</h4>Oral squamous cell carcinoma (OSCC) remains a major clinical challenge, with limited therapeutic options and poor outcomes. Among the emerging approaches to address this unmet need, spatially fractionated radiotherapy (SFRT) using mini-GRID patterns has emerged as a promising approach, delivering high radiation doses through narrowly collimated beamlets that spare intervening normal tissue and may enhance the therapeutic index. This study evaluated the efficacy and safety of mini-GRID RT in an orthotopic, syngeneic murine model of OSCC.<h4>Materials and methods</h4>C57BL/6 mice bearing MOC1 tumors were randomized to receive conventional radiotherapy (conv-RT; 20 Gy), mini-GRID RT (20 Gy average dose), or no treatment. Endpoints included survival, tumor growthClinical and translational radiation oncology101101https://www.ebi.ac.uk/biostudies/studies/S-EPMC12804384biostudies-literatureMini-GRID enhances survival and reduces toxicity in an orthotopic murine model of oral squamous cell carcinoma: A proof-of-concept study.PMC12804384Sertorio MJuchaux MSanchez-Garcia MGilbert CKolmel EGLuna-Vega VEspenon JRoncali LPrezado YAcuna-Perez MIfalseMini-GRID enhances survival and reduces toxicity in an orthotopic murine model of oral squamous cell carcinoma: A proof-of-concept study.<h4>Background and purpose</h4>Oral squamous cell carcinoma (OSCC) remains a major clinical challenge, with limited therapeutic options and poor outcomes. Among the emerging approaches to address this unmet need, spatially fractionated radiotherapy (SFRT) using mini-GRID patterns has emerged as a promising approach, delivering high radiation doses through narrowly collimated beamlets that spare intervening normal tissue and may enhance the therapeutic index. This study evaluated the efficacy and safety of mini-GRID RT in an orthotopic, syngeneic murine model of OSCC.<h4>Materials and methods</h4>C57BL/6 mice bearing MOC1 tumors were randomized to receive conventional radiotherapy (conv-RT; 20 Gy), mini-GRID RT (20 Gy average dose), or no treatment. Endpoints included survival, tumor growth2026-01-01T00:00:00Z2026 Mar2026-06-12T04:54:26.555Z2026-06-12T03:08:06.879ZS-EPMC128043844155276110.1016/j.ctro.2025.101101